New corporate member

IPC is pleased to welcome Arcutis Biotherapeutics, Inc. as a 2022 Bronze Level Corporate Member. Arcutis, based in Westlake Village, CA, is a medical dermatology company founded in 2016 that champions meaningful innovation to solve the most persistent challenges of patients with immune-mediated dermatological diseases and conditions. “We are delighted to welcome Arcutis Biotherapeutics, Inc. to the IPC family, and look forward to partnering with them to improve the care of people with psoriasis worldwide, through education, research and advocacy,” said IPC CEO Christy Langan.

More information about Arcutis can be found at https://www.arcutis.com/.

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Mona El-Kalioby, MBBCh, MSc, MD

Psoriasis and the Pandemic: Lessons Learned from PsoProtect

Boehringer Ingelheim’s SPEVIGO® Receives Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA)

Also Read

Fellowship Program

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Mona El-Kalioby, MBBCh, MSc, MD

Learn about Mona El-Kalioby’s experience as a 2022 participant in IPC’s International Fellowship Program. In this exclusive interview, she shares how the program helped her personally and professionally.

Tuesday, May 30, 2023

Fellows

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Juul van den Reek, MD, PhD

Learn about Juul van den Reek’s experience as a 2022 participant in IPC’s International Fellowship Program. In this exclusive interview, she shares how the program helped her expand her psoriasis research internationally and build valuable connections with experts in the field.

Wednesday, April 26, 2023

IPC

Meet our Newest Councilors

Introducing IPC’s newest Councilors for 2023: A cohort of global experts dedicated to improving patient care for psoriasis.

Monday, April 24, 2023

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

New corporate member

Categories

Recent Posts

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Mona El-Kalioby, MBBCh, MSc, MD

Psoriasis and the Pandemic: Lessons Learned from PsoProtect

Boehringer Ingelheim’s SPEVIGO® Receives Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA)

Also Read

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Mona El-Kalioby, MBBCh, MSc, MD

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Juul van den Reek, MD, PhD

Meet our Newest Councilors

Subscribe to the IPC Newsletter

Quick Links

Follow us